产程中阿片类镇痛与早产儿神经发育结局
本研究为多中心随机对照试验的二次分析,纳入1404例早产单胎活产儿,比较产程中使用与未使用 parenteral 阿片类镇痛对2岁内神经发育及围产结局的影响。
要点
- 产程中使用 parenteral 阿片类镇痛未增加早产儿2岁时神经发育迟缓风险。
- 其余围产结局在两组间无显著差异。
核心结论
- 在易发生神经损伤的早产儿人群中,产程中暴露于 parenteral 阿片类药物与2岁内神经发育迟缓风险增加无关,围产结局亦未更差。
研究设计与样本
- 多中心随机对照试验(评估镁预防早产儿脑瘫)的二次分析,纳入1404例妊娠<37周分娩的单胎、无畸形活产儿的产妇。
- 排除暴露或主要结局数据缺失、接受全身麻醉或报告使用海洛因或未指定违禁药物的产妇。
- 根据产程中是否使用 parenteral 阿片类(静脉或肌注)镇痛分组,主要结局为24月龄时 Bayley 婴儿发育量表II评估的任何精神运动或智力发育迟缓。
主要发现
- 535例(38%)接受了 parenteral 阿片类镇痛。
- 调整后分析显示,2岁时精神运动或智力发育迟缓无显著差异(aOR 0.96;95%CI 0.76-1.20)。
临床怎么用
- 对于早产风险孕妇,产程中使用 parenteral 阿片类镇痛对子代2岁内神经发育无显著不良影响,可据此进行镇痛决策。
局限性
- 本研究为二次分析,原试验主要目的为评估镁对脑瘫的预防作用,可能影响结果的解释。
- 暴露组与非暴露组在基线特征上存在差异,尽管进行了多变量调整,仍可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are concerns regarding neurobehavioral changes in infants exposed to parenteral opioids during labor; however, long-term neurodevelopment remains unstudied. OBJECTIVE: We aimed to examine the association between parenteral opioids used as labor analgesia and perinatal outcomes and childhood neurodevelopment until 2 years of age among infants born prematurely. We hypothesized that intrapartum exposure to parenteral opioids is associated with impaired neurodevelopment and adverse perinatal outcomes. STUDY DESIGN: This was a secondary analysis of a multicenter, randomized controlled trial assessing magnesium for the prevention of cerebral palsy in infants at risk for preterm birth. Women delivering a singleton, nonanomalous, live infant before 37 weeks' gestation were considered for inclusion. Women were excluded if they had missing exposure or primary outcome data, were exposed to general anesthesia, or reported use of heroin or unspecified illicit drugs. Women reporting use of nonopioid illicit drugs such as cocaine and marijuana were not excluded. Groups were compared based on exposure or nonexposure to parenteral opioids (intravenous or intramuscular) used as labor analgesia. The primary outcome was any psychomotor or mental developmental delay at 24 months according to the Bayley Scales of Infant Development II. Secondary outcomes were the Bayley Scales of Infant Development II subdomains and adverse perinatal outcomes. Multivariable logistic regression models were performed and adjusted odds ratios with 95% confidence intervals were estimated. RESULTS: Of the 1404 women included, 535 (38%) received parenteral opioids as labor analgesia. Women receiving parenteral opioids were more likely to be younger, Hispanic, and present with cervical dilation ≥4 cm. Parenteral opioid recipients had lower rates of illicit nonopioid drug or tobacco use, a lower rate of cesarean delivery, lower educational level and were less likely to be undergoing induction. Women receiving parenteral opioids who underwent cesarean delivery were less likely to do so because of a nonreassuring fetal status. In the unadjusted and adjusted analyses, there were no significant differences in the primary outcomes of psychomotor or mental developmental delay at 2 years of age (adjusted odds ratio, 0.96; confidence interval, 0.76-1.20). The only significant difference in secondary outcomes was a shorter O2 requirement duration in the parenteral opioid group (2 vs 4 days; P=.002). CONCLUSION: Among a population of preterm infants vulnerable to neurologic impairment, intrapartum exposure to parenteral opioids was not associated with an increased risk for neurodevelopmental delay up to 2 years of age, nor did these infants have worse perinatal outcomes.
引用
- Robbins LS, Perez WM, Casey BM, et al. Intrapartum opioid analgesia and childhood neurodevelopmental outcomes among infants born preterm. Am J Obstet Gynecol MFM. 2021. PMID: 33831589. doi:10.1016/j.ajogmf.2021.100372
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。